GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

Summary

This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.

Timeline

Start

2025-01-14

Primary completion

2028-01-13

Completion

2028-01-13

Drugs

Indications